<DOC>
	<DOCNO>NCT02777008</DOCNO>
	<brief_summary>Single- multiple-ascending dose study CTP-543 healthy volunteer .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics CTP-543 Healthy Subjects</brief_title>
	<detailed_description>This two-part study ass , healthy volunteer , fast condition , sequential manner , safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) single- multiple-ascending dos CTP-543 .</detailed_description>
	<criteria>Healthy adult male females 18 50 year age , inclusive Body weight â‰¥ 50 kg BMI within range 18 30 kg/m2 , inclusive History clinically significant central nervous system ( eg , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal ( GI ) condition PR interval &gt; 220 msec QRS duration &gt; 120 msec QTcF interval &gt; 450 msec obtain screen visit prior first dose study drug History herpes zoster Hemoglobin , white blood cell , platelet level low reference limit screen prior first dose study drug Liver function test great upper limit normal Positive blood screen human immunodeficiency virus ( HIV antibody ) , hepatitis B virus surface antigen , hepatitis C virus antibody Urinalysis positive protein glucose A positive screen alcohol , drug abuse , tobacco use Donation blood , plasma blood product prior screen A positive tuberculosis test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>